Sumitomo Chemical reported a 20% year-on-year rise in net profit to ₹214.5 crore for the quarter ended June 30, 2026 (Q1FY27), driven by operational efficiency gains and a one-time exceptional item. Revenue from operations increased modestly by 1% to ₹1,063.3 crore, while EBITDA expanded by 6% to ₹233.3 crore. The profit surge was significantly aided by an exceptional gain of ₹26.9 crore from an insurance claim related to a fire incident at the Bhavnagar plant during FY23. This filing was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The financial performance reflects strong margin expansion despite minimal top-line growth. Gross profit rose 4% to ₹416.7 crore, with gross margins improving by 111 basis points to 39.2%. Operating leverage was evident as employee expenses grew only marginally compared to revenue, allowing operating EBITDA to climb 6% to ₹233.3 crore. The EBITDA margin widened by 120 basis points to 21.9%, up from 20.7% in Q1FY26. Net profit before tax surged 20% to ₹288.2 crore, benefiting from both operational improvements and the non-recurring insurance receipt.

Financial Performance Highlights

What the Numbers Show

The divergence between flat revenue growth and double-digit profit expansion highlights the impact of the exceptional item on bottom-line figures. Excluding the ₹26.9 crore insurance gain, underlying profitability still showed strength, with EBITDA margins expanding due to controlled operating expenses. Other income also contributed positively, rising to ₹47.3 crore from ₹38.8 crore in the prior year quarter. The company noted that business seasonality makes annual monitoring more relevant than quarterly comparisons.

Board Reconstitution

Sumitomo Chemical announced a major reconstitution of its Board of Directors effective September 1, 2026. Dr. Suresh Ramachandran will be appointed as Managing Director, succeeding Chetan Shantilal Shah, whose term as Managing Director concludes on August 31, 2026. Mr. Shah will transition to a Non-Executive Non-Independent Director role and is expected to be considered for Chairman. Mukul Govindji Asher’s term as Chairman and Independent Director also ends on August 31, 2026. N. Sivaraman will be re-appointed as an Independent Director until August 31, 2029, and Anand Mohan Tiwari will join as an Independent Director until August 30, 2028.

Working Capital and Balance Sheet

Working capital dynamics shifted during the quarter. Inventory levels rose to ₹883.6 crore from ₹766.1 crore at the end of March 2026, increasing inventory days to 124 from 149. Trade receivables decreased to ₹799.8 crore from ₹735.6 crore, though receivable days improved to 68 from 83. Net working capital stood at ₹497.8 crore as of June 2026. The company maintains a debt-free balance sheet, with total assets reaching ₹4,474.2 crore at the end of FY26.

Sumitomo Chemical India Limited declared a dividend of ₹1.30 per equity share and approved key leadership transitions at its 26th Annual General Meeting (AGM) held on July 27, 2026. The meeting, conducted via Video Conferencing (VC) and Other Audio Visual Means (OAVM), also sanctioned material related-party transactions with Sumitomo Chemical Company, Limited for the financial year 2026-27.

The AGM commenced at 02:30 P.M. with 65 members present, satisfying the quorum requirements under the Companies Act, 2013 and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Dr. Mukul G. Asher, Chairman of the Board of Directors, chaired the proceedings. All Directors, Statutory Auditors, Secretarial Auditors, and the Scrutinizer attended the meeting. The Company Secretary & Compliance Officer, Deepika Trivedi, submitted the proceedings to BSE Limited and The National Stock Exchange of India in compliance with Regulation 30, Part – A of Schedule – III of the SEBI (LODR) Regulations, 2015.

Key Resolutions Passed

Shareholders approved ordinary and special resolutions covering financial statements, dividends, and board appointments. The detailed voting outcomes are summarized below:

Leadership Transitions

The board restructuring involves significant role changes effective from late August and early September 2026. Dr. Suresh Ramachandran, currently Deputy Managing Director, will be promoted to Managing Director starting September 1, 2026. Concurrently, Mr. Chetan Shah, whose tenure as Managing Director concludes on August 31, 2026, will transition to the role of Non-Executive Non-Independent Director from September 1, 2026. Shareholders also approved the payment of advisory fees, commission, and sitting fees to Mr. Shah for one year from his new appointment date.

Two new Independent Directors were appointed to strengthen the board’s oversight capabilities. Mr. N. Sivaraman was reappointed for a second term of three years, effective September 1, 2026. Mr. Anand Mohan Tiwari was appointed for a term of two years, effective August 31, 2026. Dr. Suresh Ramachandran was also re-appointed as a Director after retiring by rotation.

Related Party Transactions and Compliance

The AGM approved material related-party transactions entered into and proposed to be entered into with Sumitomo Chemical Company, Limited during the Financial Year 2026-27. This approval ensures continued operational synergy while maintaining regulatory compliance. The remuneration of M/s. GMVP & Associates LLP, the Cost Auditors, was ratified by shareholders. Mr. Kamalax G. Saraf was appointed as Scrutinizer, with Mr. Mandar K. Saraf as alternate, to supervise the e-voting process. The final voting results will be disseminated to exchanges and published on the company’s website.